TargetBeta
TNFRSF17
TNF receptor superfamily member 17 · also BCM, CD269, TNFRSF13A, BCMA · CD molecules
22 programs in company-led studies act on TNFRSF17, from 17 companies: 9 in phase 3, 3 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (14 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| linvoseltamabrule | Regeneron Pharmaceuticals | phase 4 | 1312 running | CD3E | NCIt |
| teclistamabrule | Johnson & Johnson | phase 4 | 1110 running | CD3E | NCIt |
| elranatamabrule | Pfizer | phase 4 | 159 running | CD3E | NCIt |
| belantamab mafodotinrule | GlaxoSmithKline | phase 3 | 2518 running | – | NCIt |
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 1212 running | CD19 | a judged reading |
| etentamig | AbbVie | phase 3 | 1111 running | CD3E | the company's pipeline |
| ramantamig | Johnson & Johnson | phase 3 | 77 running | CD3E, GPRC5D | a judged reading |
| anitocabtagene autoleucelrule | Gilead Sciences | phase 3 | 66 running | – | NCIt |
| equecabtagene autoleucelrule | Nanjing IASO Biotechnology | phase 3 | 54 running | – | NCIt |
| Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 | Sino Biopharmaceutical | phase 3 | 44 running | CD3E | the company's pipeline |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 44 running | CD3E, GPRC5D | NCIt |
| Evarucabgene Autoleucelrule | Nexcella | phase 3 | 22 running | – | NCIt |
| Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytesrule | Cartesian Therapeutics | phase 2 | 64 running | – | NCIt |
| cizutamigrule | UCB | phase 2 | 52 running | CD3E | NCIt |
| belantamab | GlaxoSmithKline | phase 2 | 32 running | – | the company's pipeline |
| vonsetamigrule | Regeneron Pharmaceuticals | phase 2 | 32 running | CD3E | NCIt |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 22 running | CD38, CD3E | the company's pipeline |
| pamlectabart tismanitinrule | Heidelberg Pharma | phase 2 | 22 running | – | NCIt |
| Allogeneic Anti-BCMA CAR T-cells AZD4045 | AstraZeneca | phase 2 | 11 running | – | a judged reading |
| BCMA-CD19 Compound CAR T Cellsrule | iCell Gene Therapeutics | phase 1 | 33 running | CD19 | NCIt |
| LVV Expressing VSV Glycoprotein/Anti-CD3 scFv Containing Transgene Encoding for Anti-BCMA CAR KLN-1010rule | Kelonia Therapeutics | phase 1 | 11 running | CD3E | NCIt |
| tunlucabtagene autoleucel | Bristol-Myers Squibb | phase 1 | 11 running | GPRC5D | a judged reading |
Conditions their studies are in
- Multiple Myeloma, 21 programs
- Amyloidosis, 4 programs
- Lupus Erythematosus, Systemic, 4 programs
- Immunoglobulin Light-chain Amyloidosis, 3 programs
- Myasthenia Gravis, 2 programs
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, 1 program
- Autoimmune Diseases, 1 program
- Food Hypersensitivity, 1 program
- Hematologic Neoplasms, 1 program
- Lupus Nephritis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026anitocabtagene autoleucel · Gilead Sciences · phase 3 · NCT05396885
- Dec 2026Evarucabgene Autoleucel · Nexcella · phase 3 · NCT06097832
- Dec 1, 2026Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes · Cartesian Therapeutics · phase 2 · NCT06038474
- Dec 31, 2026GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003 · Innovent Biologics · phase 3 · NCT07764861
- Feb 2027etentamig · AbbVie · phase 3 · NCT06223516
- Feb 1, 2027Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F · AstraZeneca · phase 3 · NCT06530849
- Feb 12, 2027teclistamab · Johnson & Johnson · phase 4 · NCT07030517
- Mar 2027LVV Expressing VSV Glycoprotein/Anti-CD3 scFv Containing Transgene Encoding for Anti-BCMA CAR KLN-1010 · Kelonia Therapeutics · phase 1 · NCT07075185
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.